Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission: To promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Presented by: Alida LP Caforio, MD, PhD (1), Cristina Basso, MD,PhD(2), Loira Leoni, MD, PhD (1), and Renzo Marcolongo, MD(3)
(1) Cardiology, and (2) Cardiovascular Pathology, Department of Cardiological, Thoracic, and Vascular Sciences, (3) Haematology and Clinical Immunology, Department of Medicine,University of Padova, Padova, Italy
A 37 year old male, who practiced agonist sport activity (cycling, soccer), with negative family and personal history for heart disease underwent cardiological consultation as outpatient because of prolonged palpitation unrelated to effort. Standard 12 lead ECG was within normal limits. 24 h ECG Holter monitoring showed: sinus rhythm, 4771 polymorphic ventricular ectopic beats (VEBs), 887 in couples, 86 non sustained ventricular tachycardia (NSVT) runs (longest 5 beats, max 120 bpm), sinus rhythm, mean heart rate 72 (range 43-143). He underwent standard 2D echocardiography (2D-Echo) which was within normal limits. The cardiologist diagnosed arrhythmia in a normal heart, prescribed propafenone 150 mg tid and advised to reduce sport activity. After 9 months, the patient experienced prolonged palpitation and prolonged epigastric pain, increased with respiratory acts, after a training session and was admitted to the local hospital. He had a normal ECG, but abnormal Troponin I (TnI) levels, normal biventricular function on 2D Echo, sporadic frequent VEBs on telemetric monitoring, stable increase in TnI (2-3 microg/L, normal range 0,00-0,045, flat curve, normal CK-MB, normal Reactive C Protein). Coronary angiography was performed and revealed normal coronary arteries. He refused to undergo cardiovascular magnetic resonance imaging (CMRI) because of claustrophobia. He was put on atenolol 100 mg o.d. and discharged. Six months later he was referred to our institution as outpatient, still complaining of palpitation and chest pain. High sensitivity TnI was 4,214 microg/L (normal 0,00-0,045) and had tested positive on repeated occasions in the previous months. Standard ECG was within normal limits. 24 ECG Holter monitoring showed: sinus rhythm, mean HR 69 (46-103), 4345 VEBs, 711 couplets, 150 NSVT runs (longest 3 beats). 2D-echocardiography was normal, left ventricular ejection fraction (LVEF) was 67%. He had high titre serum antinuclear autoantibody (ANA) (1/5000), and was anti-heart autoantibody (AHA), and anti-intercalated disk autoantibody (AIDA) positive.
1) Can we make the final diagnosis based on the above cited results and what are the possible etiologies of this non-ischemic persistent troponin release and ventricular arrhythmia?
2) If not, which additional examination would you recommend?
3) Would you recommend an implantable defibrillator (ICD) for primary prevention?
4) Would you prescribe non steroidal anti-inflammatory drugs (NSAIDs) and colchicine?
Presented by: Fernando Dominguez, MD; Pablo Garcia-Pavia, MD, PhD
Heart Failure and Inherited Cardiac Diseases Unit.Hospital Universitario Puerta de Hierro, Madrid, Spain.
The patient presents a type of restrictive cardiomyopathy characterized by extensive fibrosis of the endocardium. These findings can be observed in two diseases: late-stage Löffler endocarditis (LE) and endomyocardial fibrosis (EMF). The former is seen in association with eosinophilic states such as hypereosinophilic syndrome, eosinophilic leukaemia, lymphomas, drug hypersensitivity or parasites. As the eosinophil count was normal in our patient, this would be extremely rare and only possible in a late fibrotic phase. This LE phase is preceded by other two. The first is characterized by intense myocarditis and necrosis with high peripheral eosinophil counts of more than 1500 per mm3. Patients usually present with weight loss, fever and cough as well as heart failure, but in this case the patient did not present such an aggressive course before fibrosis was established. After several months, this necrotic phase is followed by a thrombotic stage where the inflamed myocardium is replaced by thrombotic material (1,2). In our case the thrombus was evidenced when fibrosis was already present, so this previous phase cannot be confirmed. An endomyocardial biopsy in this setting would be especially useful in the early phases, as eosinophils are a target for specific treatments such as corticosteroids (3). However, during the late fibrotic stage the EMB would only show scar tissue.
Regarding endomyocardial fibrosis (EMF), it is usually found in tropical and subtropical regions, mainly in Africa (4). Contrary to what happens in LE, eosinophilia is not always present and it usually appears when there is a concomitant parasitic infection. Aside from infections, other possible causes include genetic factors, anti-myosin antibodies or exposure to high levels of cerium, which is very common in the typical diet of the aforementioned regions. The clinical manifestations are not as aggressive as in LE, so clinical worsening develops in a more progressive manner. Fibrosis can affect right, left or both ventricles, and the echocardiogram usually show a restrictive filling pattern, as well as obliterated LV or RV apex and a bright appearance of the endocardium. EMB confirms the diagnosis but due to the irreversible nature of fibrotic tissue, it does not enable to initiate a tailored treatment (5).
Finally, another less common endomyocardial disease would be endocardial fibroelastosis, but this rare condition is usually diagnosed in early childhood and can be associated with other congenital heart diseases (6).
The diagnosis in this case was difficult to establish, but the clinical picture resembled that of EMF, even though it appeared outside tropical or subtropical regions. This is an extremely rare condition that has been only anecdotally reported in literature (7).
A right ventricle EMB was performed in this patient, but due to the patchy nature of the disease and taking into account that fibrosis was predominantly seen in the LV, there was no fibrotic tissue in the available samples. The only findings were interstitial inflammation without eosinophils and an isolated hemangioma (Figure 7). Therefore, EMB did not confirm the diagnosis and it did not led to changes in the treatment. In a different case scenario such as peripheral eosinophilia, EMB would have been very useful in order to start effective therapy if a LE was diagnosed, but in this case it was not strictly necessary to perform an EMB.
Figure 7. Endocardium histology. Hematoxilin & eosin staining. Mild intersticial inflammation without eosinophils and central isolated hemangioma.
Once the cardiac transplant was performed, the explanted heart was analysed and showed a mildly hypertrophied left ventricle with a global wall thickness of 13 mm. The entire left ventricular endocardium was covered by a 3 mm-thick white fibrous layer (Figure 8, black arrows). The right ventricle also presented a fibrous layer in the apex, but it was normal in size and wall thickness was preserved.
The myocardium showed no scars and the coronary arteries were normal.
Figure 8. Explanted heart. Endomyocardial fibrosis in the left ventricle (black arrows)
© 2016 European Society of Cardiology. All rights reserved